Clinical Outcome in Posthysterectomy Cervical Cancer Patients Treated With Concurrent Cisplatin and Intensity-Modulated Pelvic Radiotherapy: Comparison With Conventional Radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 5, 2007, Pages 1438-1444

  Chen, Miao Fen ^a   Tseng, Chih Jen ^a   Tseng, Ching Cheng ^a   Kuo, Yuen Chun ^a   Yu, Chun Yen ^a   Chen, Wen Cheng ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Cervical cancer; Conventional Box RT; IMRT; Toxicity

Indexed keywords

CHEMOTHERAPY; DRUG PRODUCTS; PATHOLOGY; RADIOTHERAPY; TOXICITY; TUMORS;

CERVICAL CANCER; CONVENTIONAL BOX-RT; GASTROINTESTINAL (GI); IMRT; POSTHYSTERECTOMY;

PATIENT TREATMENT;

CISPLATIN;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CHRONIC TOXICITY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION INJURY; TREATMENT OUTCOME; UROGENITAL TRACT INJURY; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, INTENSITY-MODULATED; UTERINE CERVICAL NEOPLASMS;

EID: 33947524585     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.11.005     Document Type: Article

References (25)

1. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340 (1999) 1154-1161
2. Sedlis A., Bundy B.N., Rotman M.Z., et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecological Oncology Group Study. Gynecol Oncol 73 (1999) 177-183
3. Landoni F., Maneo A., Colombo A., et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350 (1997) 535-540
4. Curtin J.P., Hoskins W.J., Venkatraman E.S., et al. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): A randomized phase III trial. Gynecol Oncol 61 (1996) 3-10
5. Lai C.H., Hong J.H., Hsueh S., et al. Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: An analysis of 891 cases. Cancer 85 (1999) 1537-1546
6. Bandy L.C., Clarke-Pearson D.L., Soper J.T., et al. Long-term effects on bladder function following radical hysterectomy with and without postoperative radiation. Gynecol Oncol 26 (1987) 160-168
7. Barter J.F., Soong S.J., Shingleton H.M., et al. Complications of combined radical hysterectomy-postoperative radiation therapy in women with early stage cervical cancer. Gynecol Oncol 32 (1989) 292-296
8. Mundt A.J., Lujan A.E., Rotmensch J., et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 52 (2002) 1330-1337
9. Portelance L., Chao K.S., Grigsby P.W., et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys 51 (2001) 261-266
10. Roeske J.C., Lujan A., Rotmensch J., et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys 48 (2000) 1613-1621
11. Montz F.J., Holschneider C.H., Solh S., et al. Small bowel obstruction following radical hysterectomy: Risk factors, incidence, and operative findings. Gynecol Oncol 53 (1994) 114-120
12. Peters III W.A., Liu P.Y., Barrett II R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18 (2000) 1606-1613
13. Ryu H.S., Chun M., Chang K.H., et al. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. Gynecol Oncol 96 (2005) 490-495
14. Mundt A.J., Roeske J.C., Lujan A.E., et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol 82 (2001) 456-463
15. Ahamad A., D'Souza W., Salehpour M., et al. Intensity-modulated radiation therapy after hysterectomy: Comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. Int J Radiat Oncol Biol Phys 62 (2005) 1117-1124
16. Roeske J.C., Bonta D., Mell L.K., et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol 69 (2003) 201-207
17. van de Bunt L., van der Heide U.A., Ketelaars M., et al. Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression. Int J Radiat Oncol Biol Phys 64 (2005) 189-196
18. Georg P., Georg D., Hillbrand M., et al. Factors influencing bowel sparing in intensity modulated whole pelvic radiotherapy for gynaecological malignancies. Radiother Oncol 80 (2006) 19-26
19. Green J.A., Kirwan J.M., Tierney J.F., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet 358 (2001) 781-786
20. Beriwal S., Jain S.K., Heron D.E., et al. Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy. Gynecol Oncol 102 (2006) 195-199
21. Gerszten K., Colonello K., Heron D.E., et al. Feasibility of concurrent cisplatin and extended field radiation therapy (EFRT) using intensity-modulated radiotherapy (IMRT) for carcinoma of the cervix. Gynecol Oncol 102 (2006) 182-188
22. Salama J.K., Mundt A.J., Roeske J., et al. Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies. Int J Radiat Oncol Biol Phys 65 (2006) 1170-1176
23. Mundt A.J., Mell L.K., and Roeske J.C. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 56 (2003) 1354-1360
24. Lujan A.E., Mundt A.J., Yamada S.D., et al. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 516-521
25. Mell L.K., Kochanski J.D., Roeske J.C., et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 1356-1365